# Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis

**Authors:** Kim M. Pabst, Sophie C. Siegmund, Adrien Holzgreve, Hans P. Schmid, Timo Bartel, Ken Herrmann, Alina T. Küper, Can Aydogdu, David Kersting, Claudia Kesch, Boris A. Hadaschik, Marcus Unterrainer, Christian G. Stief, Clemens C. Cyran, Rudolf A. Werner, Wolfgang P. Fendler, Jozefina Casuscelli, Lena M. Unterrainer

PMC · DOI: 10.1007/s00259-025-07674-5 · European Journal of Nuclear Medicine and Molecular Imaging · 2025-11-25

## TL;DR

This study shows that [68Ga]Ga-FAPI-46 PET scans detect more metastatic urothelial cancer lesions than CT scans and provide better contrast than FDG PET.

## Contribution

The largest bi-centric analysis comparing [68Ga]Ga-FAPI-46 PET with CT and FDG PET in metastatic urothelial cancer.

## Key findings

- [68Ga]Ga-FAPI-46 PET detected 98% of lesions compared to 90% with CT.
- It showed higher tumour-to-background ratios than FDG PET.
- FDG PET detected all lesions but with lower contrast.

## Abstract

[68Ga]Ga-FAPI-46 has shown promise for urothelial cancer (UC) detection. This study evaluates its diagnostic value versus contrast-enhanced CT (ceCT) and 2-[18F]FDG PET in the largest bi-centric cohort to date.

Patients with metastatic UC undergoing [68Ga]Ga-FAPI-46 PET at University Hospitals Munich or Essen were retrospectively reviewed. Detection rates were compared with ceCT on a regional basis (primary, lymph nodes, visceral organs, bone). SUVmax and SUVmean of two index lesions were recorded. In a sub-cohort, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET were compared on a lesion basis. Clinical follow-up and/or histopathology served as reference.

Thirty-four patients underwent [68Ga]Ga-FAPI-46 PET/CT and ceCT, including 10 (29%) with additional 2-[18F]FDG PET/CT. Across 98 lesions (n = 65 regions), [68Ga]Ga-FAPI-46 PET detected n = 96 (98%) and ceCT n = 88 (90%), with mismatch findings in eight lymph nodes (PET positive/ceCT negative) and two visceral organs (ceCT positive/PET negative). In the subgroup comparison, 78 lesions were detected in total ([68Ga]Ga-FAPI-46: n = 72 (92%); 2-[18F]FDG: n = 78 (100%)). Tumour uptake was comparable (SUVmax [68Ga]Ga-FAPI-46 PET vs. 2-[18F]FDG: 10.2 (IQR, 1.9) vs. 8.0 (IQR, 3.3), p = 0.249), whereas [68Ga]Ga-FAPI-46 provided higher tumour-to-background ratios (Tumour-to-liver: 12.7 (IQR, 10.3) vs. 3.8 (IQR, 1.9), p = 0.046; tumour-to-spleen: 8.4 (IQR, 6.6) vs. 4.6 (IQR, 0.6), p = 0.016).

[68Ga]Ga-FAPI-46 PET demonstrated higher regional detection rates than ceCT in UC patients, particularly for lymph node metastases. Compared to 2-[18F]FDG, it provided superior tumour-to-background contrast but detected slightly fewer lesions. [68Ga]Ga-FAPI-46 PET may complement established imaging in selected scenarios, although its role in routine UC staging remains investigational.

The online version contains supplementary material available at 10.1007/s00259-025-07674-5.

## Linked entities

- **Chemicals:** [68Ga]Ga-FAPI-46 (PubChem CID 164888937)
- **Diseases:** urothelial carcinoma (MONDO:0040679)

## Full-text entities

- **Diseases:** Tumour (MESH:D009369), UC (MESH:D014523), lymph node metastases (MESH:D008207)
- **Chemicals:** 2-[18F]FDG (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013314/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013314/full.md

---
Source: https://tomesphere.com/paper/PMC13013314